Drugs / Combivent®
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | COMBIVENT | — | 1996-10-24 | fda.gov ↗ |
Trials 0
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02182869 Comparator | Apr → Aug 2001 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00628758 Background | Dec 2005 → Sep 2008 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02177253 Comparator | Oct 2002 → Mar 2004 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02592122 Comparator | Oct 2013 → Oct 2016 | obstructive lung disease | snow | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Combivent | “Combivent inh 100 mcg/dosage” NCT00628758 ↗ |
| Known as | Salbutamol Aerosol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02592122 ↗ |
| Route | Inhaled | “COMBIVENT Inhalation Aerosol” NCT02177253 ↗ |